News | May 12, 2015

Combined Radiation and Hormonal Therapy Improves Survival in Node-Positive Prostate Cancer

Study of large national database reveals that combination therapy reduced death risk by 50 percent, compared with hormone therapy alone

MGH Cancer Center, node-positive prosate cancer, radiation therapy, survival

May 12, 2015 — A new study finds men with prostate cancer that has spread to nearby lymph nodes can benefit from the addition of radiation therapy to treatments that block the effects of testosterone. This combination therapy would be most effective in patients at significant risk of dying from node-positive prostate cancer. The report from investigators at the Massachusetts General Hospital (MGH) Cancer Center and the American Cancer Society has been published online in the Journal of the National Cancer Institute.

Nearly half of the patients studied nationwide with node-positive prostate cancer were not receiving combination therapy, the study found, which could potentially save their lives.

"Our analysis of a large national database revealed that adding radiation therapy to androgen-deprivation therapy decreased the risk of death in these patients by 50 percent over five years," said Jason Efstathiou, M.D., D.Phil., of the MGH Cancer Center and Department of Radiation Oncology, senior author of the study. "It appears that more aggressive local management of prostate cancer confined to the pelvis can offer more durable disease control, prevent the disease from spreading further and, for some patients, even provide a potential cure."

Whether prostate cancer has spread from the prostate gland to nearby lymph nodes can be determined either by biopsy or imaging; current tumor-staging practices put patients with node-positive disease in the same category as those whose tumor has metastasized to other parts of the body, such as bone or lung. Common thinking has been that tumors not confined to the prostate gland cannot be cured but can sometimes be controlled and patients' survival extended by androgen-deprivation therapy (ADT) — which blocks testosterone's stimulation of tumor growth — radiation therapy or other treatments. Efstathiou noted that the findings of this study potentially have important implications for such staging systems.

Current practice guidelines from the National Comprehensive Cancer Network support treating node-positive cancer with either ADT alone or with ADT plus radiation. While some evidence has suggested that adding radiation therapy improves outcomes for node-positive disease, limited data to support that possibility have been reported. The current study — designed to examine treatment practice across the country and compare patient outcomes — analyzed information from the National Cancer Data Base, which includes 70 percent of the newly diagnosed cancer cases in the U.S. every year.

In a population of more than 3,500 men diagnosed with node-positive prostate cancer from 2004 to 2011, the research team found that almost 52 percent had received ADT plus radiation, 32 percent received ADT alone, 6 percent received only radiation and 10 percent received neither. Focusing on a statistically matched group of 636 patients — 318 who were treated with ADT alone and 318 who received ADT plus radiation therapy — revealed that the death rate among those receiving combination therapy was around 50 percent lower than it was in patients receiving ADT alone over the five years after diagnosis.

"Optimal management of prostate cancer that has spread to regional lymph nodes remains largely undefined, and our finding that nearly half of such patients may be undertreated despite being at a high risk for cancer death suggests that reevaluation of current practice guidelines may be warranted," said Efstathiou, who is an associate professor of radiation oncology at Harvard Medical School. "Our results need to be validated by prospective and randomized studies, but they strongly imply that adding radiation therapy to ADT for node-positive prostate cancer can provide a survival benefit, possibly leading to durable disease control or even cure."

For more information: www.massgeneral.org/cancer

Related Content

BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Overlay Init